Answers are grounded in this paper and cite their sources.
Atrasentan, a selective endothelin receptor ETA antagonist, is a new potential molecule in the treatment of proteinuric glomerulopathies, especially IgA nephropathy. Current studies confirm its benefit in reducing proteinuria. In combination with currently used renoprotective drugs, atrasentan may significantly contribute to reducing renal damage and thus slowing the progression of chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Silvie Rajnochová Bloudíčkova (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: